期刊文献+

地西他滨治疗老年急性髓系白血病患者的疗效及安全性评价 被引量:1

Efficacy and Safety of Decitabine in the Treatment of Elderly Patients with Acute Myeloid Leukemia
在线阅读 下载PDF
导出
摘要 目的探讨老年急性髓系白血病患者临床治疗中地西他滨的应用疗效与安全性。方法方便选择该院于2018年1—12月期间收治的老年急性髓系白血病患者40例,以患者就诊日期的奇偶性以及个人意愿为标准,20例为观察组,20例为对照组,对照组患者接受常规CAG方案治疗,观察组患者以对照组患者治疗方案为基础,接受地西他滨治疗,比对两组患者的临床治疗有效率(ORR)以及并发症发生率。结果观察组患者的临床治疗有效率(ORR)为85.00%,对照组患者的临床治疗有效率(ORR)为50.00%,两组间差异有统计学意义(χ^2=5.584,P<0.05);观察组患者的并发症发生率为30.00%,对照组患者的并发症发生率为75.00%,两组间差异有统计学意义(χ^2=8.120,P<0.05)。结论老年急性髓系白血病患者临床治疗期间,行CAG方案化疗的基础上,接受地西他滨治疗,疗效确切,且可以减少并发症的发生,为患者的预后提供安全保障,值得推广。 Objective To investigate the efficacy and safety of decitabine in the clinical treatment of elderly patients with acute myeloid leukemia.Methods A total of 40 patients with acute myeloid leukemia admitted to the hospital from January 2018 to December 2018 were convenient selected.The parity of the patient's visit date and personal wishes were used as the standard.20 patients were in the observation group and 20 patients in the control group.Patients in the control group received conventional CAG regimen.The patients in the observation group were treated with decitabine based on the treatment plan of the control group.The clinical treatment efficiency(ORR)and the incidence of complications were compared between the two groups.Results The clinical treatment efficiency(ORR)of the observation group was 85.00%,and the clinical treatment efficiency(ORR)of the control group was 50.00%.The difference between the two groups was statistically significant(χ^2=5.584,P<0.05);the complication rate was 30.00%in the observation group and 75.00%in the control group.The difference between the two groups was statistically significant(χ^2=8.120,P<0.05).Conclusion In the clinical treatment of elderly patients with acute myeloid leukemia,on the basis of CAG chemotherapy,the treatment with decitabine is effective,and can reduce the occurrence of complications,and provide a safety guarantee for the prognosis of patients.It is worth promoting.
作者 任海云 REN Hai-yun(Department of Hematology and Oncology,Jinxiang County People's Hospital,Jinxiang,Shandong Province,272200 China)
出处 《中外医疗》 2019年第30期8-10,共3页 China & Foreign Medical Treatment
关键词 急性髓系白血病 老年患者 CAG 地西他滨 疗效观察 并发症发生率 Acute myeloid leukemia Elderly patients CAG Decitabine Efficacy observation Complication rate
  • 相关文献

参考文献15

二级参考文献98

  • 1蔡成森,孙爱宁,仇惠英,何广胜,唐晓文,金正明,傅琤琤,吴德沛.地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察[J].中华临床医师杂志(电子版),2012,6(19):6092-6094. 被引量:13
  • 2Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia [J ]. Leukemia, 2015,29(4) : 770 -775.
  • 3Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how.'? [J]. Leuk Lymphoma, 2014,55(5): 979-987.
  • 4Wei G, Ni W, Chiao JW, et al. A meta-analysis of CAG( cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1 029 patients with acute myeloid leukemia and myelodysplastic syndrome [ J]. J Hematol Oncol, 2011,4.46.
  • 5Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without aU-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment[J ]. Cancer, 2007,109(6) : 1114 - 1124.
  • 6Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[ J]. J Clin Oncol, 2012,30 (21) : 2670 - 2677.
  • 7Becker H, Suciu S, Ruter B, et al. Low-dose decitabine vs best supportive care in older patients with AML and low blast counts: Results of a subgroup analysis of the randomized phase III study 06011 of the eortc leukemia cooperative group and German MDS study group[ J ]. Blood, 2013,122 (21) : 1452.
  • 8Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J]. Cancer, 2015,121 i4) : 556 -561.
  • 9Brothman AH, Persons DL, Shaffer LG. Nomenclature evolution:Changes in the ISCN from the 2005 to the 2009 edition [J].Cytogenet Genome Res, 2009, 127 ( 1 ) : 1-4. doi:' 10. 1159/000279442.
  • 10Bumes E, Rzonsa S, Hutterer M, et al. Adverse event gradingfollowing CTCAE v3. 0 underestimates hypertensive side effects inpatients with glioma treated with Bevacizumab [ J ]. J Neurooncol,2016,127(1) ;191-200. doi; 10. 1007/sll060-015-2031-7.

共引文献107

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部